Vertex Pharmaceuticals made headlines with a 14% share price jump, despite an overall market dip, thanks to clinical wins and ...

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market. What Are Smart Beta ETFs? The ...

Canada Gairdner Awards recognize the world’s most accomplished researchers whose work is improving our understanding of human ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

The Value Fund finished Q1 +3.0% net of fees and expenses. Markets had a challenging start to 2025, with elevated volatility across the major indices. The top contributor to the portfolio in Q1 was ...

As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, ...

LONDON - The European Commission has approved a label expansion for Vertex Pharmaceuticals’ (NASDAQ:VRTX) cystic fibrosis medication, KAFTRIO® (ivacaftor ...

Though things might not go that far, it's still worth planning ahead. Vertex Pharmaceuticals is best known for developing cystic fibrosis (CF) drugs. In patients with this condition, the normally ...

She noted from strengthening Covid-related pharmacovigilance systems (processes designed to monitor the safety of pharmaceutical products, particularly after they have been approved for use ...

— We have everything you need: full data on over 800 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & ...

However, if these Indian pharmaceutical players are unable to hike their costs, it may result in a shutdown of production. Generic products can command only very lower margins, therefore ...